Bridgebio Pharma Stock Market Value
| BBIO Stock | USD 27.49 1.05 3.97% |
| Symbol | BridgeBio |
BridgeBio Pharma Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 1.194 | Quarterly Revenue Growth (0.33) | Return On Assets (0.49) | Return On Equity (17.90) |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BridgeBio Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BridgeBio Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BridgeBio Pharma.
| 10/28/2024 |
| 11/27/2024 |
If you would invest 0.00 in BridgeBio Pharma on October 28, 2024 and sell it all today you would earn a total of 0.00 from holding BridgeBio Pharma or generate 0.0% return on investment in BridgeBio Pharma over 30 days. BridgeBio Pharma is related to or competes with Blueprint Medicines, Amylyx Pharmaceuticals, Day One, Terns Pharmaceuticals, Apellis Pharmaceuticals, PTC Therapeutics, and Krystal Biotech. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases More
BridgeBio Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BridgeBio Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BridgeBio Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.9 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 19.79 | |||
| Value At Risk | (5.46) | |||
| Potential Upside | 6.76 |
BridgeBio Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BridgeBio Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BridgeBio Pharma's standard deviation. In reality, there are many statistical measures that can use BridgeBio Pharma historical prices to predict the future BridgeBio Pharma's volatility.| Risk Adjusted Performance | 0.0284 | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.53) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.076 |
BridgeBio Pharma Backtested Returns
BridgeBio Pharma appears to be not too volatile, given 3 months investment horizon. BridgeBio Pharma secures Sharpe Ratio (or Efficiency) of 0.062, which signifies that the company had a 0.062% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for BridgeBio Pharma, which you can use to evaluate the volatility of the firm. Please makes use of BridgeBio Pharma's Risk Adjusted Performance of 0.0284, mean deviation of 2.72, and Downside Deviation of 2.9 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, BridgeBio Pharma holds a performance score of 4. The firm shows a Beta (market volatility) of 1.25, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BridgeBio Pharma will likely underperform. Please check BridgeBio Pharma's jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether BridgeBio Pharma's price patterns will revert.
Auto-correlation | 0.22 |
Weak predictability
BridgeBio Pharma has weak predictability. Overlapping area represents the amount of predictability between BridgeBio Pharma time series from 28th of October 2024 to 12th of November 2024 and 12th of November 2024 to 27th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BridgeBio Pharma price movement. The serial correlation of 0.22 indicates that over 22.0% of current BridgeBio Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.22 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 2.84 |
BridgeBio Pharma lagged returns against current returns
Autocorrelation, which is BridgeBio Pharma stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BridgeBio Pharma's stock expected returns. We can calculate the autocorrelation of BridgeBio Pharma returns to help us make a trade decision. For example, suppose you find that BridgeBio Pharma has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BridgeBio Pharma regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BridgeBio Pharma stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BridgeBio Pharma stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BridgeBio Pharma stock over time.
Current vs Lagged Prices |
| Timeline |
BridgeBio Pharma Lagged Returns
When evaluating BridgeBio Pharma's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BridgeBio Pharma stock have on its future price. BridgeBio Pharma autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BridgeBio Pharma autocorrelation shows the relationship between BridgeBio Pharma stock current value and its past values and can show if there is a momentum factor associated with investing in BridgeBio Pharma.
Regressed Prices |
| Timeline |
Pair Trading with BridgeBio Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BridgeBio Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BridgeBio Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against BridgeBio Stock
| 0.5 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.37 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.34 | OPT | Opthea | PairCorr |
The ability to find closely correlated positions to BridgeBio Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BridgeBio Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BridgeBio Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BridgeBio Pharma to buy it.
The correlation of BridgeBio Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BridgeBio Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out BridgeBio Pharma Correlation, BridgeBio Pharma Volatility and BridgeBio Pharma Alpha and Beta module to complement your research on BridgeBio Pharma. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
BridgeBio Pharma technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.